Key result
Empaglif
RCT (n=1,517)
Randomized
Yes
Answers are grounded in this paper and cite their sources.
This editorial announces the Circulation Journal Awards for the Year 2017, highlighting eight outstanding clinical and experimental cardiovascular studies.
The aim of these Awards is to recognize papers published in 2017, both clinical and experimental studies, that were highly appreciated by the Editorial Team. The selection process comprises 2 steps. In the first step, from 256 original papers published in the Journal in 2017, our 40 Japanese Associate Editors selected papers with a high scientific level in their respective fields, and in the second step, the 4 Associate Editorial Teams (10 on 1 team) further evaluated the selected papers in terms of originality, contribution to cardiovascular science, manner of paper preparation, and future possibilities.
No takes yet. Share an insight, caveat, or question.
Toyoaki Murohara (2018) conducted an RCT in Type 2 diabetes and established cardiovascular disease (n=1,517). Empagliflozin vs. Placebo was evaluated on 3-point MACE (composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) (HR 0.68, 95% CI 0.48-0.95, p=0.0872 for treatment by race interaction). Empaglif.
Synapse has enriched 10 related papers. Consider them for comparative context: